Glioblastoma: State of the Art and Future Trends
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: closed (30 April 2024) | Viewed by 5009
Special Issue Editor
2. Hospital Clínic de Barcelona, 08036 Barcelona, Spain
Interests: adult and pediatric nervous tumor tissue; genomic approach; epigenomic approach; immunohistochemical approach; clinical biomarkers; new technologies
Special Issue Information
Dear Colleagues,
Glioblastoma multiforme (GB) remains one of the most complex and challenging diseases despite decades of collaborative and multidisciplinary efforts, with a median survival rate of just 15 months. The most relevant research findings were incorporated by the WHO in its fifth edition of the "Central Nervous System Tumor Classification" published in 2021, in which nomenclature was modified and integrated diagnosis was consolidated, providing pathologists, clinicians, and researchers with a more defined framework for tumor and patient management. However, while our understanding of the molecular and genetic features of both pediatric and adult GB and other high-grade astrocytomas has advanced significantly in recent years, we still face many challenges in deciphering the complex biology of these tumors. Overcoming these obstacles will be crucial for the identification of novel therapeutic targets, the development of effective treatments, and ultimately, the improvement of patient outcomes. Multidisciplinary research efforts, the integration of multi-omics data, and the application of advanced computational methods will be essential in addressing these challenges and progress in the battle against glioblastoma.
In this Special Issue, we aim to bring together the most exciting advances since 2021 in the fields of molecular neuropathology, cell biology, bioinformatics, bioengineering, imaging, genetics, and other related fields that help us better understand the biology of this tumor. Novel technologies such as single-cell sequencing, CRISPR/Cas9 gene editing, and AI, to name just a few of the latest, are more powerful than ever and are certain to pave the way toward a holistic understanding of this devastating tumor.
I would like to invite the GB research community to share their knowledge in this Special Issue dedicated to "Glioblastoma: State of the Art and Future Trends" with original articles or reviews that show the current state of knowledge about these tumors and open new paths to be able to improve the outcome of patients with this devastating disease. We want to look through the keyhole and see a brighter and more hopeful future for our glioblastoma patients as soon as possible.
Thank you in advance and I look forward to your participation in this important discussion.
Sincerely,
Dr. Teresa Ribalta
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- glioblastoma
- pediatric high-grade glioma
- integrated histomolecular diagnosis
- molecular neuropathology
- artificial intelligence (AI)
- bioengineering
